PT-2385

DB16055InvestigationalSmall molecule

PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).

Chemical structure of PT-2385
Formula / weight
C17H12F3NO4S · 383.34 g/mol (avg)
Code names
PT-2385

Resolves to

Compound
UNII6O16716DXPCAS1672665-49-4ChEMBLCHEMBL4173075
Structure
InChIKeyONBSHRSJOPSEGS-INIZCTEOSA-NSMILESCS(=O)(=O)C1=C2[C@H](O)C(F)(F)CC2=C(OC2=CC(=CC(F)=C2)C#N)C=C1
Targets
Q16665HIF1AQ99814EPAS1

What you can answer from here — as of October 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with PT-2385, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In